Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013–2014 at the Geneva University Hospitals

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 36, Issue 2, 2017, Pages 343-350

  Andrey, D O ^a   Francois P ^a   Manzano, C ^a   Bonetti, E J ^a   Harbarth, S ^a   Schrenzel, J ^a   Kelley, W L ^b   Renzoni, A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CEPHALOSPORIN DERIVATIVE; MECA PROTEIN, STAPHYLOCOCCUS AUREUS; PENICILLIN BINDING PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING SITE; BLOOD CULTURE; BLOODSTREAM INFECTION; COMMUNITY ACQUIRED INFECTION; DISK DIFFUSION; DRUG MECHANISM; GENE SEQUENCE; GENOTYPE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUALITY CONTROL; SOFT TISSUE INJURY; TANDEM REPEAT; UNIVERSITY HOSPITAL; WOUND INFECTION; ANTIBIOTIC RESISTANCE; CLASSIFICATION; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; ITALY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR TYPING; MUTATION; PREVALENCE; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HOSPITALS, UNIVERSITY; HUMANS; ITALY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; MUTATION; PENICILLIN-BINDING PROTEINS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS;

EID: 84991329764     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-016-2807-5     Document Type: Article

References (34)

1. Von Dach E, Diene SM, Fankhauser C, Schrenzel J, Harbarth S, François P (2016) Comparative genomics of community-associated methicillin-resistant Staphylococcus aureus shows the emergence of clone ST8-USA300 in Geneva, Switzerland. J Infect Dis 213(9):1370–1379. doi:10.1093/infdis/jiv489
2. Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B, Olearo F, Emonet S, Uçkay I (2015) Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother 70(1):264–272. doi:10.1093/jac/dku352
3. Harrison EM, Ba X, Blane B, Ellington MJ, Loeffler A, Hill RL, Holmes MA, Peacock SJ (2016) PBP2a substitutions linked to ceftaroline resistance in MRSA isolates from the UK. J Antimicrob Chemother 71(1):268–269. doi:10.1093/jac/dkv317
4. Peacock SJ, Paterson GK (2015) Mechanisms of methicillin resistance in Staphylococcus aureus. Annu Rev Biochem 84:577–601. doi:10.1146/annurev-biochem-060614-034516
5. Zhong NS, Sun T, Zhuo C, D’Souza G, Lee SH, Lan NH, Chiang CH, Wilson D, Sun F, Iaconis J, Melnick D (2015) Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis 15(2):161–171. doi:10.1016/S1473-3099(14)71018-7
6. Sader HS, Farrell DJ, Flamm RK, Jones RN (2016) Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US medical centers. Surg Infect 17(4):443–447. doi:10.1089/sur.2015.209
7. Fishovitz J, Rojas-Altuve A, Otero LH, Dawley M, Carrasco-López C, Chang M, Hermoso JA, Mobashery S (2014) Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics. J Am Chem Soc 136(28):9814–9817. doi:10.1021/ja5030657
8. Kelley WL, Jousselin A, Barras C, Lelong E, Renzoni A (2015) Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998. Antimicrob Agents Chemother 59(4):1922–1930. doi:10.1128/AAC.04068-14
9. Sader HS, Flamm RK, Jones RN (2013) Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis 76(1):61–68. doi:10.1016/j.diagmicrobio.2013.01.005
10. Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE (2015) In vitro activity of ceftaroline against Staphylococcus aureus isolated in 2012 from Asia-Pacific countries as part of the AWARE Surveillance Program. Antimicrob Agents Chemother 60(1):343–347. doi:10.1128/AAC.01867-15
11. Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF (2016) In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme. J Antimicrob Chemother 71(1):162–169. doi:10.1093/jac/dkv311
12. Zhang H, Xiao M, Kong F, O’Sullivan MV, Mao LL, Zhao HR, Zhao Y, Wang H, Xu YC (2015) A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology. Int J Antimicrob Agents 45(4):347–350. doi:10.1016/j.ijantimicag.2014.12.014
13. Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez KK, Musick WL, Rosato AE, Musser JM (2014) PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 58(11):6668–6674. doi:10.1128/AAC.03622-14
14. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF (2008) In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52(6):2089–2096. doi:10.1128/AAC.01403-07
15. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD (2014) Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother 69(8):2065–2075. doi:10.1093/jac/dku114
16. Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowska-Shick K (2012) Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 67(6):1321–1324. doi:10.1093/jac/dks069
17. Schaumburg F, Peters G, Alabi A, Becker K, Idelevich EA (2016) Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA. J Antimicrob Chemother 71(1):41–44. doi:10.1093/jac/dkv325
18. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-López C, Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D, Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso JA (2013) How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci U S A 110(42):16808–16813. doi:10.1073/pnas.1300118110
19. Fishovitz J, Hermoso JA, Chang M, Mobashery S (2014) Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. IUBMB Life 66(8):572–577. doi:10.1002/iub.1289
20. Fishovitz J, Taghizadeh N, Fisher JF, Chang M, Mobashery S (2015) The Tipper–Strominger hypothesis and triggering of allostery in penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus (MRSA). J Am Chem Soc 137(20):6500–6505. doi:10.1021/jacs.5b01374
21. Lahiri SD, Alm RA (2016) Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline. J Antimicrob Chemother 71(1):34–40. doi:10.1093/jac/dkv329
22. Lahiri SD, McLaughlin RE, Whiteaker JD, Ambler JE, Alm RA (2015) Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline. J Antimicrob Chemother 70(9):2488–2498. doi:10.1093/jac/dkv131
23. Fernandez R, Paz LI, Rosato RR, Rosato AE (2014) Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance. Antimicrob Agents Chemother 58(10):5736–5746. doi:10.1128/AAC.03019-14
24. Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY (2016) Whole-genome sequencing of methicillin-resistant Staphylococcus aureus resistant to fifth-generation cephalosporins reveals potential non-mecA mechanisms of resistance. PLoS One 11(2), e0149541. doi:10.1371/journal.pone.0149541
25. Strommenger B, Layer F, Klare I, Werner G (2015) Pre-use susceptibility to ceftaroline in clinical Staphylococcus aureus isolates from Germany: is there a non-susceptible pool to be selected? PLoS One 10(5), e0125864. doi:10.1371/journal.pone.0125864
26. Fankhauser C, Schrenzel J, Francois P, Pittet D, Harbarth S (2015) Secular trends of methicillin-resistant Staphylococcus aureus (MRSA) at Geneva University Hospitals (HUG) over a 14-year period. In: Antimicrobial Resistance and Infection Control: Abstracts from the 3rd International Conference on Prevention and Infection Control (ICPIC 2015), Geneva, Switzerland, June 2015. Abstract 09
27. Renzoni A, Huggler E, Kelley WL, Lew D, Vaudaux P (2009) Increased uptake and improved intracellular survival of a teicoplanin-resistant mutant of methicillin-resistant Staphylococcus aureus in non-professional phagocytes. Chemotherapy 55(3):183–188. doi:10.1159/000215304
28. Francois P, Huyghe A, Charbonnier Y, Bento M, Herzig S, Topolski I, Fleury B, Lew D, Vaudaux P, Harbarth S, van Leeuwen W, van Belkum A, Blanc DS, Pittet D, Schrenzel J (2005) Use of an automated multiple-locus, variable-number tandem repeat-based method for rapid and high-throughput genotyping of Staphylococcus aureus isolates. J Clin Microbiol 43(7):3346–3355. doi:10.1128/JCM.43.7.3346-3355.2005
29. Koessler T, Francois P, Charbonnier Y, Huyghe A, Bento M, Dharan S, Renzi G, Lew D, Harbarth S, Pittet D, Schrenzel J (2006) Use of oligoarrays for characterization of community-onset methicillin-resistant Staphylococcus aureus. J Clin Microbiol 44(3):1040–1048. doi:10.1128/JCM.44.3.1040-1048.2006
30. Campanile F, Bongiorno D, Borbone S, Stefani S (2009) Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy. Ann Clin Microbiol Antimicrob 8:22. doi:10.1186/1476-0711-8-22
31. Vaudaux P, Huggler E, Bernard L, Ferry T, Renzoni A, Lew DP (2010) Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob Agents Chemother 54(9):3861–3870. doi:10.1128/AAC.00269-10
32. Francois P, Harbarth S, Huyghe A, Renzi G, Bento M, Gervaix A, Pittet D, Schrenzel J (2008) Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993–2005. Emerg Infect Dis 14(2):304–307. doi:10.3201/eid1402.070229
33. Jousselin A, Renzoni A, Andrey DO, Monod A, Lew DP, Kelley WL (2012) The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 56(7):3629–3640. doi:10.1128/AAC.06264-11
34. Jousselin A, Manzano C, Biette A, Reed P, Pinho MG, Rosato AE, Kelley WL, Renzoni A (2015) The Staphylococcus aureus chaperone PrsA is a new auxiliary factor of oxacillin resistance affecting penicillin-binding protein 2A. Antimicrob Agents Chemother 60(3):1656–1666. doi:10.1128/AAC.02333-15